Protein-bound Uremic Retention Solutes and Long Nocturnal Hemodialysis: a Longitudinal Analysis
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Although remarkable progress has been made, chronic kidney disease still poses a major burden on both individual patients, as well as on society as a whole. There is a strong inverse relationship between decreasing renal function, as estimated by glomerular filtration rate, and mortality rate, especially death due to cardiovascular disease. The exact cause(s) remain to be elucidated. Uremic toxins might play an important role.
In the course of decreasing renal function the concentration of numerous intracellular and extracellular compounds vary from the non-uremic state. A still increasing number of uremic retention solutes are being identified. Renal replacement strategies aim to remove potentially harmful substances from the body. Traditionally much attention has been paid to small water-soluble molecules such as urea nitrogen and creatinine. Based on the results of the recent HEMO and ADEMEX studies, increases of small water-soluble solute removal above the level reached with modern dialysis techniques (HD, PD) seem not to be advantageous with regard to patient outcome. These findings may point to the importance of other distinct groups of uremic retention solutes. In view of the data described above, protein-bound solutes might be good candidates.
Several advantages of long duration hemodialysis have been observed, including a better control of blood pressure by decreasing extracellular fluid volume, lowering peripheral vascular resistance and improving endothelium-dependent and -independent vasodilation. A normalization of heart rate variability and improvement of left-ventricular function was noted as well. Furthermore, anemia control has been shown to be easier and several nutritional parameters improved in patients treated with long duration HD. The therapy results in higher small water-soluble solute removal, phosphate removal and greater elimination of larger molecules (e.g. β2-microglobulin).
It seems an appealing question whether a better control of the serum levels of protein-bound solutes can be achieved by long duration (nocturnal) hemodialysis. This might be another advantage of this therapeutic modality, or may even in part explain the better outcome of patients treated this way.
The study compares intermittent hemodialysis with long nocturnal hemodialysis with respect to serum concentrations of several protein bound uremic toxins, as well as solute removal.
| Condition | Intervention |
|---|---|
|
End Stage Kidney Disease |
Procedure: hemodialysis |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | A Multicentric Observational Trial on Protein Bound Uremic Toxins in Nocturnal Hemodialysis |
serum, urine, dialysate
| Estimated Enrollment: | 20 |
| Study Start Date: | December 2006 |
| Estimated Study Completion Date: | December 2011 |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1
hemodialysis, four hours, twice weekly
|
Procedure: hemodialysis
individualised
|
|
2
hemodialysis, eight hours, twice weekly
|
Procedure: hemodialysis
individualised
|
|
3
hemodialysis, eight hours, every other day
|
Procedure: hemodialysis
individualised
|
|
4
hemodialysis, eight hours, six days per week
|
Procedure: hemodialysis
individualised
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
maintenance dialysis patients
Inclusion Criteria:
- Start hemodialysis during 2007
- Age over 18 years
- Informed consent
Exclusion Criteria:
- Non consent
Contacts and Locations| Australia, Victoria | |
| Monash Medical Centre | |
| Clayton, Victoria, Australia, 3168 | |
| Geelong Hospital | |
| Geelong, Victoria, Australia, 3220 | |
| Belgium | |
| Universitaire Ziekenhuizen Leuven | |
| Leuven, Brabant, Belgium, 3000 | |
| Virga Jesseziekenhuis | |
| Hasselt, Limburg, Belgium, 3500 | |
| Principal Investigator: | Björn KI Meijers, MD | Universitaire Ziekenhuizen Leuven |
| Study Director: | Pieter Evenepoel, MD, PhD | Universitaire Ziekenhuizen Leuven |
| Principal Investigator: | Tom Dejagere, MD | Virga Jesse Ziekenhuis |
| Principal Investigator: | Nigel Toussaint, MD | Geelong Hospital |
More Information
Publications:
| Responsible Party: | Björn Meijers, Prof, Universitaire Ziekenhuizen Leuven |
| ClinicalTrials.gov Identifier: | NCT00417339 History of Changes |
| Other Study ID Numbers: | NHD002 |
| Study First Received: | December 28, 2006 |
| Last Updated: | September 28, 2011 |
| Health Authority: | Belgium: Institutional Review Board |
Keywords provided by Universitaire Ziekenhuizen Leuven:
|
hemodialysis dialysis adequacy uremic retention solute |
Additional relevant MeSH terms:
|
Kidney Diseases Kidney Failure, Chronic Urologic Diseases Renal Insufficiency, Chronic Renal Insufficiency |
ClinicalTrials.gov processed this record on June 18, 2013